EUVIMEDEUVIMED entdecken
Crossref

Deficient Mismatch Repair and BRAF Mutations in Metastatic Colorectal Cancer in the South Island of New Zealand

Jeremy Yap iD, Sharon Pattison

Asia-Pacific Journal of Clinical Oncology · 2025

DOI: 10.1111/ajco.14151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Jeremy Yap und 1 weiteren Autor:innen. Beteiligte Einrichtung: Southern Blood and Cancer Service, Health New Zealand/Te Whatu Ora - Southern, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, DNA Mismatch Repair. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Manatū Hauora, the Ministry of Health of New Zealand (NZ), published minimum standards for molecular testing of colorectal cancers (CRCs) in June 2018. These included mismatch repair (MMR) testing at diagnosis and BRAF V600E mutation analysis on newly diagnosed stage IV CRCs. This study aimed to determine the proportion of patients with CRC in the South Island of NZ with metastatic deficient mismatch repair (dMMR) CRC, the proportion of metastatic CRCs and dMMR CRCs that have a BRAF V600E mutation, and audit testing for BRAF mutations and appropriate referral to genetics services.

Methods

People from the South Island with histologically diagnosed colorectal adenocarcinoma between July 1, 2018, and June 30, 2019, were identified by the National Cancer Registry. Data points extracted from the electronic medical record included staging, MMR status, BRAF mutation testing, and genetics referral.

Results

A total of 845 patients met the inclusion criteria; 166 of 845 (19.6%) had dMMR CRC, and of these 130 (78%) had BRAF mutation, 256 patients developed metastatic disease by data cut‐off, 20 (7.8%) had dMMR, and 41 (22.2%) had BRAF mutation. When indicated, 275 of 330 (83.3%) were tested for BRAF mutation and 32 of 45 (71.1%) referred to genetics. Compared with other populations, South Island CRC patients had higher rates of dMMR and BRAF mutation.

Conclusion

Less than 10% of patients ( n = 20) had metastatic dMMR CRC. These patients could be considered candidates for immune checkpoint inhibitor therapy, a small number that would not significantly burden the NZ health system if funded. The vast majority of dMMR CRC was sporadic. Rates of testing could be improved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafColorectal NeoplasmsDNA Mismatch RepairHumansNew ZealandFemaleMaleMiddle AgedAgedMutationAdultAged, 80 and over

Stichwörter der Autor:innen

BRAFNew Zealandcolorectal cancermicrosatellite instabilitymismatch repair

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Southern Blood and Cancer Service, Health New Zealand/Te Whatu Ora - Southern, Dunedin, New Zealand.
  • Wellington Blood and Cancer Centre, Health New Zealand/Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington, New Zealand.
  • Department of Pathology, Otago Medical School - Dunedin Campus, University of Otago, Dunedin, New Zealand.

ORCID-Profile: Jeremy Yap

Zitieren

APA

Yap, J., & Pattison, S. (2025). Deficient Mismatch Repair and BRAF Mutations in Metastatic Colorectal Cancer in the South Island of New Zealand. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14151

Vancouver

Yap J, Pattison S. Deficient Mismatch Repair and BRAF Mutations in Metastatic Colorectal Cancer in the South Island of New Zealand. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.14151

BibTeX
@article{Yap2025,
  author = {Yap, Jeremy and Pattison, Sharon},
  title = {Deficient Mismatch Repair and BRAF Mutations in Metastatic Colorectal Cancer in the South Island of New Zealand},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1111/ajco.14151}
}
Kostenlos starten →